Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Context Therapeutics Inc shares valued at $70,080 were purchased by Lehr Martin A. on Jun 09 ’25. At $0.70 per share, Lehr Martin A. acquired 100,000 shares. The insider’s holdings grew to 920,190 shares worth approximately $1.05 million following the completion of this transaction.
Also, Levit Alex C. purchased 20,000 shares, netting a total of over 11,520 in proceeds. Following the buying of shares at $0.58 each, the insider now holds 29,000 shares.
Before that, Minai-Azary Jennifer Lynn had added 40,010 shares to its account. In a trade valued at $25,486, the Chief Financial Officer bought Context Therapeutics Inc shares for $0.64 each. Upon closing the transaction, the insider’s holdings increased to 40,010 shares, worth approximately $91211.4.
As published in their initiating research note from Guggenheim on September 18, 2025, Context Therapeutics Inc [CNTX] has been a Buy and the price target has been revised to $5. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in late April. As of January 08, 2025, JMP Securities has initiated its “Mkt outperform” rating for CNTX. Earlier on November 25, 2024, D. Boral Capital initiated its rating. Their recommendation was “a Buy” for CNTX stock.
Analyzing CNTX Stock Performance
On last trading session, Context Therapeutics Inc [NASDAQ: CNTX] plunged -2.56% to $1.14. The stock’s lowest price that day was $1.1, but it reached a high of $1.255 in the same session. During the last five days, there has been a drop of approximately -0.87%. Over the course of the year, Context Therapeutics Inc shares have dropped approximately -32.14%. Shares of the company reached a 52-week high of $1.5500 on 10/10/25 and a 52-week low of $0.4900 on 05/30/25.
Support And Resistance Levels for Context Therapeutics Inc (CNTX)
According to the 24-hour chart, there is a support level at 1.0750, which, if violated, would cause prices to drop to 1.0100. In the upper region, resistance lies at 1.2300. The next price resistance is at 1.3200. RSI (Relative Strength Index) is 49.06 on the 14-day chart, showing neutral technical sentiment.
Is Context Therapeutics Inc subject to short interest?
Stocks of Context Therapeutics Inc saw a sharp rise in short interest on 2025-10-31 jumping by 0.35 million shares to 0.85 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 0.49 million shares. A jump of 41.82% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 1.71 of the overall float, the days-to-cover ratio (short ratio) jumped to 1.71.
Which companies own the most shares of Context Therapeutics Inc (CNTX)?
In terms of Context Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 5.25 in the next 12 months, up nearly 348.72% from the previous closing price of $1.17. Analysts anticipate Context Therapeutics Inc stock to reach 6 by 2025, with the lowest price target being 4.5. In spite of this, 2 analysts ranked Context Therapeutics Inc stock as Buy at the end of 2025. On May 16, 2024, Piper Sandler assigned a price target of “an Overweight” to the stock and initiated coverage with a $4.50.
